Group 1 - The core point of the article highlights that four funds under Baoying Fund experienced a decline of over 9% in 2025, with specific funds managed by Yao Yi and Zhang Ruolun showing significant losses [1][2] - Baoying Advantage Industry Mixed C and A funds reported declines of 15.66% and 15.32% respectively, with Yao Yi managing these funds since March 2021 after a tenure at Huatai Securities [1][2] - The top ten holdings of Baoying Advantage Industry Mixed fund include companies such as Bai Li Tianheng, Heng Rui Pharmaceutical, and WuXi AppTec, indicating a focus on the pharmaceutical sector [1] Group 2 - Baoying Brand Consumption Stock C and A funds recorded declines of 9.87% and 9.11% respectively, managed by Zhang Ruolun since August 2025 [1][2] - The Baoying Brand Consumption fund maintains a diversified portfolio across major consumer sectors, with top holdings including Kweichow Moutai, Tencent Holdings, and Haidilao [1][2] - The funds have been operational since 2019, with the Brand Consumption funds focusing on sectors like liquor, home appliances, and leisure food [1][2]

Group 1 - In 2025, four funds under the management of Baoying Fund experienced a decline of over 9% [1] - Baoying Advantage Industry Mixed C and A funds fell by 15.66% and 15.32% respectively, managed by Yao Yi, who has been with Baoying since 2017 [1] - The top ten holdings of Baoying Advantage Industry Mixed fund include companies like Hengrui Medicine and WuXi AppTec [1] Group 2 - Baoying Brand Consumption Stock C and A funds recorded declines of 9.87% and 9.11% respectively, managed by Zhang Ruolun since August 2025 [1] - The Baoying Brand Consumption fund diversifies its holdings across various consumer sectors, with top ten holdings including Kweichow Moutai and Tencent [1][2] - The funds have varying net asset values, with Baoying Advantage Industry Mixed A at 4.00 billion and Baoying Brand Consumption A at 0.38 billion [2]

Group 1 - In 2025, four funds under the management of Baoying Fund experienced a decline of over 9% [1] - The Baoying Advantage Industry Mixed C and A funds, managed by Yao Yi, fell by 15.66% and 15.32% respectively [1] - The top ten holdings of Baoying Advantage Industry Mixed fund include companies such as Bai Li Tian Heng, Heng Rui Pharmaceutical, and WuXi AppTec [1] Group 2 - The Baoying Brand Consumption Stock C and A funds, managed by Zhang Ruolun, declined by 9.87% and 9.11% respectively [2] - The Baoying Brand Consumption fund diversifies its holdings across various consumer sectors, including liquor, home appliances, and leisure food [1] - The top ten holdings of Baoying Brand Consumption fund include Kweichow Moutai, Tencent Holdings, and Haidilao [1]

Core Viewpoint - The performance of ordinary stock funds in China has been predominantly positive in 2023, with 97% of comparable funds reporting gains, largely driven by the semiconductor sector's strong performance. Group 1: Fund Performance - As of November 30, 2023, out of 970 comparable ordinary stock funds, 941 funds achieved positive performance, representing a 97% success rate, while only 29 funds experienced declines [1] - The top-performing funds include E Fund Strategic Emerging Industries Stock A and C, both of which saw gains exceeding 90%, primarily due to the semiconductor sector's robust growth [1] - E Fund Information Industry Select Stock A ranked third with a 89.71% increase, benefiting from similar sector trends [1] Group 2: Fund Managers and Holdings - The fund manager of E Fund Strategic Emerging Industries, Ouyang Liangqi, has a background as an industry researcher and has been managing the fund since 2023 [1] - E Fund Information Industry Select Stock A's manager, Zheng Xi, has 13 years of management experience and oversees a portfolio heavily invested in semiconductor stocks [2] - The top holdings of these funds include major companies like Tencent, Alibaba, and various semiconductor firms, indicating a concentrated investment strategy in high-growth sectors [1][2] Group 3: Underperforming Funds - Only 14 ordinary stock funds reported declines exceeding 5% in the same period, with the largest losses seen in Taikang Medical Health Stock A and C, which fell by -10.56% and -10.14% respectively [3] - The underperforming funds primarily focused on healthcare and biopharmaceutical sectors, which have not matched the growth seen in technology and semiconductor sectors [3] - The cumulative returns of some underperforming funds, such as the Shenwan Lixin Medical Pioneer Stock, showed significant losses of up to 51.99% [3]